The list includes the innovator, drug brand name, and drug substance including AbbVie-Humira (Adalimumab), Amgen-Enbrel (Etanercept), Genentech-Avastin (Bevacizumab), Biogen-Genentech-Rituxan (Rituximab), Genentech-Herceptin (Trastuzumab), Janssen Biotech-Remicade (Infliximab), Sanofi-Lantus (Insulin Glargine), Genentech-Herceptin (Trastuzumab), Novartis-Lucentis (Ranibizumab), Amgen-Neulasta (Pegfilgrastim), Amgen-Epogen (Epoetin-Alfa), Amgen-Neupogen (Filgrastim).
Humira is the highest-selling drug in 2020, followed by Eternacept, Bevacizumab, Rituxizumab, and Trastuzumab.
The Humira, from AbbVie, has crossed a whopping 20 billion dollars in sales which is far highest than any other drug in the world.
This is the reason for the same is leading in terms of the number of USFDA approved 7 biosimilars. Trastuzumab is followed by 5 approved biosimilars in the US and then the Bevacizumab which is having 4 approved biosimilars.
According to FDA, the reference is defined as the single biological product, approved by FDA, against which a proposed biosimilar product is compared while the biosimilar is defined as a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product… Markets and surveys have launched new market reports targeting biosimilars.